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A B S T R A C T
Purpose: To estimate the direct costs associated with the current management of focal epilepsy in adults
treated with a combination of antiepileptic drugs (AEDs) in France and the supplementary costs of drug
resistant epilepsy as deﬁned by the International League Against Epilepsy (ILAE) in 2009.
Methods: ESPERA was a multicentre, observational, cross-sectional study conducted in France in 2010. A
random sample of neurologists, including specialists in epilepsy, prospectively enrolled adults with focal
epilepsy treated with a combination of AEDs. Investigators classiﬁed their patients according to the 2009
ILAE criteria for drug resistance and this classiﬁcation was then reviewed by two experts. All items of
healthcare resource use associated with epilepsy over the previous year were documented
retrospectively and valued from a societal perspective.
Results: Seventy-one neurologists enrolled 405 patients. After experts’ review, 70.6% of patients were
classiﬁed with drug-resistant epilepsy, 22.4% with drug-responsive epilepsy and 7% with undeﬁned
epilepsy. The mean annual epilepsy-related direct costs per patient were s4485  s4313 in patients
with drug-resistant epilepsy compared to s1926  s1795 in patients with drug-responsive epilepsy. In
these two groups, costs of AEDs were estimated at s2603 and s1544, respectively. Patients with drug-
resistant epilepsy were more often hospitalised (mean annual cost: s1270 vs. s97) and underwent more
additional tests (mean annual cost: s194 vs. s53).
Conclusion: The direct cost of focal epilepsy in adults on AED combinations was estimated at s3850/
patient/year. Drug resistance, as deﬁned by the 2009 ILAE criteria, resulted in signiﬁcant extra costs
which varied with seizure frequency.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is one of the most common serious chronic brain
diseases with an estimated prevalence of 4–10 cases/1000
individuals worldwide [1,2]. In Europe, approximately 6 million
people suffer from active epilepsy according to the WHO report
published in 2010 [3]. It has been estimated that 40–50% of people
with epilepsy require a combination of antiepileptic drugs (AEDs)
to achieve remission [4,5] and that 15–25% of people with epilepsy
have drug-resistant epilepsy [6,7]. Approximately 36,000–48,000
persons would suffer from drug-resistant focal epilepsy in France
[8].* Corresponding author at: CEMKA-EVAL, 43 boulevard du Mare´chal Joffre, 92340
Bourg La Reine, France. Tel.: +33 1 40 91 30 30; fax: +33 1 40 91 30 31.
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1059-1311/$ – see front matter  2014 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2014.01.016The high prevalence of epilepsy and its consequences in terms
of social handicap [9] and impaired quality of life [10,11] result in
high burden both for individuals and society [3,12,13]. In Europe,
the estimates of costs associated to epilepsy vary from s13.8
billion/year in 2010 [14] to s20 billion/year [3].
In order to improve management of these patients, a working
group of the International League Against Epilepsy (ILAE)
established a consensus deﬁnition of drug-resistant epilepsy in
2009 (2009 ILAE Task Force) [15].
Despite its high burden, studies on the costs of epilepsy are
sparse. The objectives of this study were to describe the direct costs
associated with the management of adults with focal epilepsy
treated with a combination of AEDs in France and to estimate the
supplementary costs related to AED treatment resistance as
deﬁned by the 2009 ILAE criteria [15].vier Ltd. All rights reserved.
Table 1
Unit costs of the main items of healthcare resource use and sources.
Unit cost
(s2010)
Source
Outpatient care
Consultations NGAP (nomenclature ge´ne´rale
des actes professionnels)
General practitioner 23.00
Neurologist 29.00
Other medical specialist 28.00
Emergency department visit
without hospitalisation
87.40
Additional tests CCAM (classiﬁcation commune
des actes me´dicaux 2010)
EEG 57.60
Holter monitoring–EEG 145.97
Cerebral MRI 281.00
CT scan 131.28
PET SCAN 1089.54
X-ray Variable
Laboratory tests NABM (nomenclature des actes
de biologie me´dicale 2011)
Standard laboratory tests 28.08
Antiepileptic drug levels 25.25
Antiepileptic drugs Variable Dictionnaire VIDAL 2011
Hospitalisations Etude nationale de couˆt (ENCC)
2008 (total costs including all
medical costs and overhead costs)
Duration of stay <24 h 768.02
Duration of stay 24 h 3557.01
Domestic help (tariff
per hour)
13.27
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2.1. Study design
ESPERA was a multicentre, observational, cross-sectional study.
Data were collected retrospectively for the 12 months preceding
inclusion, with the exception of data on disease history and
treatment, which were collected for the entire disease course.
2.2. Investigators and patients
A sample of 880 neurologists was randomly selected from a
nationally representative listing of neurologists in France and
invited to participate in the study. In addition, we invited
speciﬁcally 321 neurologists (not included in the ﬁrst sample)
who were members of the French League against Epilepsy (LFCE).
Overall, 71 (6%) of the selected neurologists accepted to participate
(3.4% of the randomly selected neurologists and 12.8% of those
speciﬁcally invited).
Each participating neurologist was asked to enrol prospectively
from 6 to 9 consecutive patients meeting the inclusion criteria.
Were eligible all adults (age  18-years) with focal epilepsy
treated with a combination of 2 AEDs and who gave a written
informed consent. Patients treated with a combination of AEDs
including a benzodiazepine were eligible if this AED was
prescribed over the long-term. Patients participating in a clinical
trial or hospitalised at the time of the study were not eligible.
Among enrolled patients, one out of 3 had to be drug-resistant
epilepsy patients. This proportion was imposed by the protocol to
ensure that a sufﬁcient number of patients with drug-resistant
epilepsy would be included. Each investigator was also asked to ﬁll
out a register recording the main clinical characteristics of all
consecutive adult patients, treated or not, seen in consultation for
focal epilepsy during the inclusion period. This register was used to
perform further statistical adjustment intended to obtain the true
distribution of patients according to AEDs responsiveness.
2.3. Data collection
At inclusion, investigators completed a questionnaire for each
patient. This documented socio-demographic, administrative and
medical data including history of epilepsy, frequency and type of
seizures, aetiology, comorbidities and all data relating to
healthcare use: AEDs received since the diagnosis of epilepsy,
duration, dose regimens and compliance, consultations, hospita-
lisations, additional tests (laboratory tests, EEG, X-ray, MRI, CT
scan, etc.) and home care. All items of medical resources
consumption over the last year were collected by the investigators
based on their ﬁles and the interview of their patients. The study
was designed to collect all information required during the
inclusion visit.
2.4. Classiﬁcation according to treatment responsiveness
Investigators were asked to deﬁne the AED responsiveness
status of each enrolled patient according to the 2009 ILAE criteria
[15]. Patients were then classiﬁed as having drug resistant epilepsy
(‘‘drug-resistant’’ patients), drug-responsive epilepsy (‘‘drug-re-
sponsive’’ patients) or undeﬁned drug responsiveness (‘‘unde-
ﬁned’’ patients). Drug resistant epilepsy was deﬁned as failure to
achieve sustained seizure freedom, despite adequate trials of two
tolerated and appropriately chosen and used AED schedules
whether as monotherapies or in combination. Drug responsive
epilepsy was deﬁned as epilepsy, in which the patient receiving the
current AED treatment regimen, has been seizure free for a
minimum of three times the longest interseizure interval(experienced over the year preceding the initiation of the current
treatment) or for 12 months, whichever is longer [15].
The classiﬁcations established by investigators were subse-
quently reviewed by two epileptologists from the study scientiﬁc
committee according to modalities previously described [16]. All
results presented here reﬂect the classiﬁcations validated by these
experts.
2.5. Source of unit costs and estimation of costs
Our study principally evaluated the direct medical costs of
epilepsy. Healthcare resource use included consultations, hospi-
talisations, laboratory tests, other additional tests (EEG, imaging,
etc.) and AED prescription. Direct non-medical costs were limited
to payments to salaried caregivers. Valuation was carried out from
a societal perspective. The annual cost of care was calculated for
each patient by multiplying the volume of resources used during
the 12 months preceding inclusion by the unit cost of each item
concerned. The mean annual direct epilepsy-related cost per
patient, expressed in Euros (2010), was then calculated.
Table 1 lists the principal unit costs used and their source. The
unit costs of outpatient care services were estimated using current
national tariffs and fees for service ﬁxed by the French health
authorities. The unit costs of AEDs were obtained from the
Dictionnaire Franc¸ais des Me´dicaments (VIDAL 2010) [17] which
provides the current prices of drugs. Costs of AED treatments were
then estimated by multiplying the unit cost by the daily dose (after
titration if any) and duration of treatment. Unit costs of
hospitalisations for each Diagnosis Related Group (DRG) were
obtained from the 2008 Etude Nationale des Couˆts a` Me´thodologie
Commune (ENCC) [18]. This study aggregates unit costs from the
accounting system of a panel of French public and private
hospitals. In absence of hourly tariffs for salaried caregivers in
France, home care cost was estimated from the mean cost supplied
by French homecare providers.
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In order to adjust for sampling bias, the data were weighted by:
(i) the number of patients per year treated by the investigator for
focal epilepsy, (ii) the proportion of drug-resistant patients among
adult patients treated for focal epilepsy by the investigator and (iii)
the annual frequency of consultations with the investigator for
each patient.
Patient or disease characteristics that could have an impact on
the cost of management were compared by bivariate analysis. These
included AEDs responsiveness, seizure frequency, aetiology, type of
medical practice and gender. As the number of patients with
undeﬁned drug responsiveness at inclusion was relatively small,
these patients were excluded from the comparative analyses.
The signiﬁcance of the differences observed was determined
using the Chi square test (or Fisher’s exact test when the
theoretical values were <5) for categorical variables, and Student’s
t-test (or Wilcoxon test if a normal distribution was not veriﬁed)
for continuous variables. The level of signiﬁcance was ﬁxed at 5%.
All analyses were performed using SAS1 version 9.2 (North
Carolina, USA).
3. Results
Between June and October 2010, 428 patients were enrolled.
Among them, 23 were secondarily excluded because they did not
meet the inclusion criteria and/or the investigator did not ﬁll out
the requested register about all patients visiting him during the
inclusion period. The analysis was ﬁnally performed on 405
patients enrolled by 71 participating neurologists (mean: 6
patients/investigator). Sixty-one percent of neurologists were
exclusively hospital-based, 29% worked exclusively in community
practice and 10% in both sectors (Fig. 1).
According to the 2009 ILAE criteria and after experts revision,
70.6% (286/405) of the patients were classiﬁed as drug-resistant,Neurolo gists randomly 
selec ted from a naonal
database  (N=880)
Neurolo gists,  members of the 
French League Against  
Epilepsy (N=321 )
Neurolog ists con tac ted 
(N=1 201)
Neurolo gists having 
acce pted to parcipate
(N=135)
Neurolo gists having 
enroll ed at least one 
paent (N=78)
Total number
enroll ed pae
(N=428 )
Total number 
evaluab le 
paents (N=40 
Neurolo gists not havi ng 
provided the register 
(N=4)
Neurolo gists not havi ng 
enroll ed any eli gible 
paent (N=3)
Neurolog ists having 
enrolled  at least one 
evaluab le paent 
(N=71)
Fig. 1. Enrollmen22.4% (n = 91) were drug-responsive and 7.0% (n = 28) had an
undeﬁned AED responsiveness status.
3.1. Socio-demographic and clinical characteristics
The socio-demographic characteristics of the enrolled patients
are shown in Table 2. The mean age was 42.7 years (range: 18–88)
and the gender ratio (m/f) was 0.98. In patients aged 18–65 years,
almost one-quarter (24.5%) were not working because of their
epilepsy. This proportion was nearly two times higher in drug-
resistant than in drug-responsive patients (29.4% vs. 13.0%,
p = 0.0002).
Table 3 shows the main characteristics of epilepsy in the
studied population. The disease started an average of 25 years
before inclusion and the mean age at ﬁrst seizure was 17.7 years.
Epilepsy had a known cause in 64.0% of cases. Complex focal
seizures were the predominant type of seizure (78% of patients).
Just over one-half of patients (52%) had at least one seizure/month
at inclusion and 27% of patients had at least one seizure/week. Only
26% of patients had experienced no seizure during the 12 months
prior to inclusion.
3.2. Healthcare resource utilisation and antiepileptic treatments
Table 4 presents the rates of utilisation of healthcare resources
and home care over the 12 months prior to inclusion. With the
exception of consultations with a general practitioner (more
frequent among drug-responsive patients) and number of hours
of home care received (which did not differ between the groups),
use of all healthcare resources appeared to be signiﬁcantly higher
in drug-resistant than in drug-responsive patients. Compared to
drug-responsive patients, drug-resistant patients had consulted
their neurologist more often (2.9 times vs. 1.9 times, p < 0.0001)
and the proportion consulting another specialist or having
undergone laboratory tests or other additional exams (EEG,
imaging tests, etc.) for their epilepsy was nearly twofold higher.Exclud ed 
paents 
(N=23 ) Not mee ng the 
inclusio n criteria 
(N=7)
 of 
nts Enroll ed by 
invesgator s havi ng 
not sent the register
(N=16 )
of 
5) Currently treated 
with monotherapy  
(N=4)
Havi ng no t pro vided 
a wri en infor med 
consent 
(N=3)
t ﬂow-chart.
Table 2
Socio-demographic characteristics of the 405 adult patients with focal epilepsy
treated with a combination of antiepileptic drugs.
Characteristics Totala
(n = 405)
Resistant
(n = 286)
Responsive
(n = 91)
p
Age (years) 0.7240
Mean (SD) 42.7  13.6 41.9  12.8 43.4  16.1
Median 40 40 39
% male 49.4 53.9 40.3 0.0249
Level of education (%) 0.0001
Primary/elementary 19.2 15.9 22.9
College 31.3 30.1 36.5
High school 30.1 36.6 11.9
Higher studies 19.4 17.4 28.8
Professional situation (%) 0.0211
Number of patients
(age 65 years)
386 275 84
% Active (currently employed) 54.8 51.1 65.5
In protected work environment 9.8 23.2 8.6 0.0253
% Inactive 45.2 48.9 34.5
Father or mother at home 2.0 2.7 0.0
Looking for employment 7.7 8.4 6.9
Unemployedb 2.5 3.5 0.0
Handicappedc 22.8 22.9 21.5
Retired 5.6 5.6 4.3
Student 2.1 2.9 0.0
Other 1.9 2.8 1.7
Inactivity due to epilepsy
according to investigator
and/or patient
24.5 29.4 13.0 0.0002
a Total includes patients with undeﬁned status (n = 28).
b Unemployed not looking for employement.
c Unable to work due to their handicap.
SD: standard deviation.
Table 3
Medical history and clinical characteristics of the 405 adult patients with focal epileps
Characteristic Totala (n = 405) 
Family history of epilepsy (%) 8.4 
History of status epilepticus (%) 10.8 
Disease duration at inclusion (years)
Mean  SD (median) 25.1  14.5 (22.5) 
Delay between ﬁrst seizure and diagnosis (months)
Mean  SD (median) 26.1  61.0 (0.0) 
Age at ﬁrst seizure (years)
Mean  SD (median) 17.7  15.0 (15.2) 
Cause of epilepsy
Unknown (%) 36.0 
Known (%) 64.0 
Pre or perinatal cause 21.8 
Including cerebral malformations 16.3 
Cerebrovascular disease 11.6 
Sequelae of a CNS infection 9.0 
Post-traumatic epilepsy 8.1 
Cerebral tumour 5.8 
Other causes 9.8 
Type of seizureb (%)
Simple focal seizure 34.6 
Complex focal seizure 77.5 
Focal seizures, secondarily generalised 58.2 
Seizure frequency at inclusion (%) 
Seizure-free for 1 year 25.6 
3 per year 9.5 
4–11 per year 12.6 
1–3 per month 25.7 
4–30 per month 24.5 
>30 per month 2.1 
Longest ISI under previous treatment (months)
Mean  SD (median) 5.2  10.9 (1.0) 
CNS: central nervous system; SD: standard deviation; ISI: inter-seizure interval.
a Total includes patients with undeﬁned status (n = 28).
b Several responses possible.
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emergency services at least once during the last year, this was the
case for none of drug-responsive patients. Finally, hospitalisation
due to epilepsy was ten times more common in drug-resistant
patients (p < 0.0001). Overall, 18% of patients were hospitalised
because of their epilepsy (1.4 times on average). Of the 104
hospitalisations that took place, the duration of stay was <24 h in
16% of cases (mean stay duration: 8.8 days; median stay duration:
5 days).
At inclusion, 49% of patients were receiving bitherapy, 33%
tritherapy and 18% were taking four AEDs (14%) or more (4%), with
patients receiving an average of 2.7 AEDs. At inclusion, 82% of drug-
responsive patients were receiving bitherapy, while this propor-
tion was only 39% in drug-resistant patients (p < 0.0001). Over the
twelve months preceding inclusion, the most frequently pre-
scribed drugs were carbamazepine (48% of patients), levetiracetam
(45%) and lamotrigine (36%) (Table 5). In all, 213 different drug
combinations were prescribed at inclusion. Only 38% of patients
were taking one of the nine most frequently prescribed AED
combinations (to at least 2% of patients).
3.3. Annual cost of management
The mean total annual direct epilepsy-related cost for all
patients was s3850 (4112). AEDs (mean annual cost:
s2298  1711) constituted the main item of expenditure (60%),
followed by hospitalisation (26%) (Table 6). This distribution was
found in all sub-groups of patients except for drug-responsive
patients and patients managed in a community practice, for whom
the second most common items of cost were consultations and home
care respectively. For all patients included, the other cost items
represented less than 6% of the total mean annual direct epilepsy-
related cost.y treated with a combination of antiepileptic drugs.
Resistant (n = 286) Responsive (n = 91) p
8.8 8.8 0.9889
13.8 2.2 0.0021
27.0  14.4 (27.0) 18.3  12.3 (16.7) <0.0001
22.4  57.7 (0.0) 29.5  57.7 (0.0) 0.8798
15.0  12.1 (14.2) 25.1  19.6 (16.5) <0.0001
39.3 24.1
60.7 75.9 0.0270
24.4 17.3 0.0007
18.7 11.2 0.1357
12.1 12.3 0.5207
10.2 1.8 0.0074
5.6 10.2 0.0004
6.4 0.8 0.0072
3.1 33.7 <0.0001
33.8 40.6 0.2348
83.7 54.1 <0.0001
52.2 76.6 <0.0001
<0.0001
0.5 100%
10.4 –
15.6 –
35.9 –
34.5 –
3.0 –
2.7  7.0 (0.7) 12.6  17.2 (2.0) <0.0001
Table 4
Use of health care resources in the management of 405 adults with focal epilepsy treated with a combination of antiepileptic drugs over the previous 12 months.
Totala (n = 405) Resistant (n = 286) Responsive (n = 91) p
%b Mean nc % %
Consultations
Neurologist 100 2.7 100 100
General practitioner 77.1 3.4 73.1 83.5 0.0450
Other specialist 26.5 2.2 30.9 15.7 0.0045
Emergency department visit without hospitalisation 17.3 1.5 23.2 0.0 <0.0001
Hospitalisations 18.3 1.4 23.2 2.3 <0.0001
Duration of stay 24 h 4.1 – 5.7 0.1 0.0157
Duration of stay >24 h 14.3 – 17.8 2.2 <0.0001
Outpatient tests
EEG (all types included) 40.5 1.4 49.4 15.3 <0.0001
Cerebral MRI 16.0 1.1 17.0 13.1 0.3807
CT scan 8.0 1.4 10.3 0.1 0.0016
X-ray 7.1 1.4 7.9 5.8 0.4987
Antiepileptic drug levels 2.5 1.8 3.3 0.9 0.3067
Other laboratory tests 14.6 1.3 15.5 14.1 0.7471
Other tests 7.1 1.2 9.8 0.6 0.0038
Home care 5.2 4.9 4.5 1.000
No. of hours/week (for patients receiving care at home) 0.2893
Mean  SD 6.7  5.5 6.6  5.3 3.8  2.6
Median/Q1/Q3 7/3/7 7/4/7 3/3/3
Min–Max 2–40 2–40 2–8
a All patients including those with undeﬁned status (n = 28).
b Percentage of patients who received the care service at least once during the previous 12 months.
c Mean number of patients who received the care service at least once during the previous 12 months.
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higher in drug-resistant than in drug-responsive patients (s4485
vs. s1926, respectively, p < 0.0001) (Table 7). The mean annual
costs of AEDs, additional exams and hospitalisations were,
respectively, two, four and thirteen times higher in drug-resistant
than in drug-responsive patients (p < 0.0001).
With respect to seizure frequency, the mean annual direct
epilepsy-related cost was 2.6 times higher in patients having
monthly seizures than in those who had been in remission for at
least 12 months (s5043 vs. s1973, respectively, p < 0.0001); a
similar difference was found for all items of cost with the exception
of home care. This analysis also showed that the mean annual direct
cost of drug-resistant epilepsy (s4485) masked important varia-
tions in cost related to seizure frequency. This increased froms2985
when this frequency was <4 seizures/year to s6247 when seizures
occurred weekly (4/month) (p < 0.0001). Concerning the contextTable 5
Frequency of prescription of antiepileptic drugs (as % of patients) in 405 adult
patients with focal epilepsy treated with polytherapy during the previous 12
months.
Totala
(n = 405)
Resistant
(n = 286)
Responsive
(n = 91)
p
Carbamazepine 47.6 45.7 56.9 0.0619
Levetiracetam 44.9 46.2 39.6 0.2700
Lamotrigine 36.4 41.1 26.2 0.0106
Clobazam 32.8 36.3 18.7 0.0017
Valproate 28.4 26.1 38.9 0.0196
Lacosamide 19.5 27.4 – <0.0001
Oxcarbazepine 18.4 19.6 12.4 0.1195
Zonisamide 14.6 19.9 0.5 <0.0001
Phenobarbital 13.8 11.1 18.9 0.0536
Topiramate 13.0 13.5 13.2 0.9321
Pregabalin 11.2 14.0 3.4 0.0056
Clonazepam 7.9 8.9 6.8 0.5262
Phenytoin 4.2 4.2 0.6 0.1785
Vigabatrin 2.4 3.3 – 0.1212
Gabapentin 1.9 2.1 0.4 0.3426
Tiagabin 0.3 0.4 – 1.0000
Ethosuximide 0.3 – – 1.0000
Diazepam 0.2 0.3 0.2 1.0000
a All patients: including those with undeﬁned status (n = 28).of care, the mean annual direct epilepsy-related cost was nearly
twofold higher in outpatients managed by a hospital-based
neurologist compared to patients managed by a community-based
neurologist (s4041 vs. s2245, respectively, p < 0.0001). Converse-
ly, there was no signiﬁcant variation in direct costs according to
gender or aetiology.
4. Discussion
According to the new criteria for AED resistance [15], our study
estimated the proportion of drug-resistant epilepsies among adult
patients with focal epilepsy treated with combined AEDs, to be 71%
in France. This rate of drug resistance appears to be 3–3.5 times
higher than estimates in non-selected epilepsy populations (20–
25%) [7,8]. This ﬁnding, in a population where 51% of patients were
treated with >2 AEDs, is consistent with data in the literature
which show that the probability of complete remission after failure
of two AEDs is modest, <20% [19,20].
Our economic analysis estimated the mean annual direct
epilepsy-related cost to be s3850. AEDs were the main direct costs,
irrespective of the sub-group of patients considered. These ﬁndings,
in patients treated by polytherapy and mainly drug-resistant conﬁrm
data from previous studies. According to those, the cost of epilepsy
and the distribution of items of expenditure vary over the course of
the disease [21]. Studies, which included a non-selected epilepsy
population, showed that cost was usually highest in the subgroup of
newly diagnosed patients [22,23]. After the period of diagnosis,
except in surgical patients, costs tend to vary according to the
treatment response [21]. Thus, as in our study, the AEDs represented
the main component of the total direct cost in studies limited to
patients with drug-resistant or uncontrolled epilepsy [24,25] or in
subgroups of such patients [23]. In our study, the selection of patients
treated by polytherapy may explain that the cost of AEDs was also the
main contributor in patients with drug responsive epilepsy. The use
of newer generation AEDs in patients not adequately controlled with
older generation AEDs may increase signiﬁcantly the drug expendi-
ture [13,21]. In our study, 92% of drug cost was due to newer
generation AEDs. By contrast and despite the observed trend towards
an increasing use of newer generation AEDs [13], the main driver of
Table 6
Annual direct costs per patient (in Euros) in adults with focal epilepsy treated with a combination of antiepileptic drugs in France in 2010–societal perspective.
Patients Totala (n = 405)
Types of cost Mean cost % SD Minimum Median cost Maximum
Direct medical cost
Antiepileptic drugs 2298 59.7 1711 133 1915 8145
Including:
Newer generationb 2115 54.9 1727 0 1793 8086
Older generationc 183 4.8 162 0 173 974
Medical consultations 179 4.6 131 52 150 1136
Testsd 156 4.1 378 0 57 3331
Hospitalisations 991 25.7 2754 0 0 22,230
Total direct medical cost 3624 94.1 3745 272 2291 29,974
Direct non-medical cost
Home care 226 5.9 1295 0 0 27,602
Total direct cost 3850 100 4112 272 2385 31,452
a All patients including those with unknown status (n = 28).
b Vigabatrin, felbamate, gabapentin, lamotrigine, tiagabin, topiramate, oxcarbazepine, levetiracetam, zonisamide, pregabalin, lacosamide.
c Carbamazepine, clobazepam, ethosuxamide, diazepam, phenobarbital, phenytoin and valproate.
d Laboratory tests, EEG, X-rays, CT scan, MRI and other tests.
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the case in two studies [26,27] conducted in non-selected popula-
tions with epilepsy, which included newly diagnosed patients or
children which are more often hospitalised than adults [22].
In drug-resistant patients, the mean annual direct epilepsy-
related cost was s4485, the two principal items of cost, AEDs and
hospitalisations representing 58% and 28% of this cost, respectively.
Compared to the mean annual direct cost for drug-responsive
patients, drug resistance therefore results in an average supple-
mentary cost of s2560/year/patient. Comparisons with data from
other studies are difﬁcult to interpret. The differences observed may
result from differences in patient management between countries or
in the methodology used (items of cost considered, in particular in
the calculation of direct non-medical costs, type of population
studied, etc.). No other economic study in adult patients with
epilepsy treated with polytherapy has been identiﬁed. However, two
studies have provided data on the costs associated with the
management of adult patients considered to be uncontrolled by
treatment or drug-resistant. In these patients, the mean annual
direct epilepsy-related cost was estimated as s4040 by Hamer et al.
[24] in a 3-month prospective study in Germany in 2003 and s4982
by Sancho et al. [25] in a cross-sectional study in Spain in 2005. In
drug-resistant patients, we estimated the mean annual direct
epilepsy-related cost as s4263, which falls between the twoTable 7
Annual direct costs per patient (in Euros) in adults with focal epilepsy treated with a com
societal perspective.
Patients Drug-resistant (n = 286) 
Types of cost Mean cost % SD Minimum Median cost Max
Direct medical cost
Antiepileptic drugs 2603 58.0 1731 180 2059 81
Including:
Newer generationa 2426 54.1 1735 0 1950 80
Older generationb 177 3.9 168 0 145 9
Medical consultations 196 4.4 141 52 161 10
Testsc 194 4.3 437 0 58 33
Hospitalisations 1270 28.3 3109 0 0 22,2
Total direct medical cost 4263 95.1 4080 349 3098 29,9
Direct non-medical cost
Home care 222 4.9 1254 0 0 27,6
Total direct cost 4485 100 4313 349 3223 29,9
a Vigabatrin, felbamate, gabapentin, lamotrigine, tiagabin, topiramate, oxcarbazepin
b Carbamazepine, clobazepam, ethosuxamide, diazepam, phenobarbital, phenytoin a
c Laboratory tests, EEG, X-rays, CT scan, MRI and other tests.previous estimates with a similar distribution of the two predomi-
nant items of cost in the three countries. AEDs and hospitalisations
represented 61% and 30%, respectively, of the mean annual direct
epilepsy-related cost in France vs. 59% and 28% in Germany and
Spain. Published data do not allow to explain the differences
observed between our study and that of Hamer et al. [24]. The small
difference in costs observed between France and Spain (in
populations with a comparable mean age and disease duration)
are mainly due to additional tests and medical consultations which
appeared to be more frequent in Spain; for example, over one year,
92% of Spanish patients required emergency services compared with
23% of French patients. Similarly, 93% of patients received at least
one structural MRI in Spain compared with 27% in France (all types of
MRI and CT scan included). These differences could be a result of the
criteria used for the deﬁnition of drug-resistance by Sancho et al.
[25] which were more restrictive than the 2009 ILAE criteria [15] and
may have led to the inclusion of more severe patients in Spain.
However, differences in use of additional exams could also be
explained by a potential underestimation of these investigations in
France. In our study, no additional test was reported in 30% of drug-
resistant patients. As a conservative hypothesis, these patients were
considered not to have undergone any additional test during the
study period. This choice could have led to an underestimate of
use and therefore the cost of this item of care. However, it shouldbination of antiepileptic drugs in France in 2010 according to AED responsiveness–
Drug-responsive (n = 91) p
imum Mean cost % SD Minimum Median cost Maximum
45 1544 80.1 1431 133 1144 5479 <0.0001
96 1337 69.4 1474 0 975 5479 <0.0001
74 207 10.8 152 0 272 756 0.0213
86 130 6.7 79 52 121 468 <0.0001
31 53 2.8 104 0 0 1009 <0.0001
30 97 5.0 653 0 0 4446 <0.0001
74 1824 94.7 1823 272 1447 9818 <0.0001
02 102 5.3 595 0 0 5520 0.6893
74 1926 100 1795 272 1447 9818 <0.0001
e, levetiracetam, zonisamide, pregabalin, lacosamide.
nd valproate.
M. de Ze´licourt et al. / Seizure 23 (2014) 349–356 355be noted that this item of cost represented only 2–6.8% of the mean
annual direct epilepsy-related cost in recent studies that included
drug-resistant patients [23–25].
Seizure frequency is one of the principal determinants of the
cost of epilepsy [10,22–24,28]. In our study, the mean annual direct
epilepsy-related cost increased signiﬁcantly with seizure frequen-
cy. However, costs were very similar when the total number of
experienced seizures varied between 1 and 11/year. The mean
annual direct epilepsy-related cost for patients with monthly
seizures (s5043) was nearly three times higher than in patients in
remission for at least 12 months (s1973). Likewise, in drug-
resistant patients, large differences in the mean annual direct
epilepsy-related cost were observed depending on seizure
frequency. The mean supplementary cost associated with drug-
resistance increased signiﬁcantly with seizure frequency from
s1060/patient/year for <4 seizures/year to s4320 for weekly
seizures (4 seizures/month).
In our study, and in contrast to the observations of Sancho et al.
[25], the mean annual direct epilepsy-related cost also varied with
the setting: it was signiﬁcantly higher for patients managed in
hospital than for those managed in community practice although
neurologists in community practice and those in hospitals
managed a similar proportion of drug-resistant patients. This
can be explained by differences in the clinical proﬁles of these
patients, with hospital neurologists tending to see more severe
patients, with a higher rate of monthly seizures (57% vs. 35%,
p < 0.0001) and of hospitalisations (22% vs. 5%, p = 0.0003) than did
neurologists in community practice.
Lastly, the study also conﬁrmed the large diversity of AED
combinations prescribed, a feature also observed by Sancho et al.
[25]. This large diversity reﬂects the pragmatic character of
therapeutic strategies [1,29,30]. It may be explained by the high
prevalence of drug-resistance in our population leading to frequent
modiﬁcations of treatment, by the need for practitioners to adapt
treatments to the clinical characteristics of their patients (age,
side-effects, comorbidities, etc.) and by the fact that the
comparative efﬁcacy of different AED combinations is poorly
documented [29,30].
Several limitations of this study should be considered in
interpreting the results. Firstly, it was carried out on a speciﬁc sub-
group of patients, namely adults with focal epilepsy treated with
polytherapy, which represents the most severe forms of epilepsy in
adults [29,31]. Furthermore, the direct non-medical costs consid-
ered in our study were limited to paid home care. They did not take
into account the costs of transport or management of side-effects
of AED treatment and were therefore underestimated. We also did
not estimate the indirect costs of the disease which represent the
largest part of the overall cost in many studies [13,32] and can be as
much as 85% of the total cost of epilepsy [33].
Another limitation of the study is related to the method for
collection of medical resources consumption in the previous year.
Investigators were asked to collect these data by consulting their
medical records during the inclusion visit and to ask patients to
complete these data when they were missing from their records.
This may have led to an underestimation of costs as the patients
may not have recalled all relevant medical consumption in the
previous year.
It should also be noted that, since there is no data available on
the number of neurologists specialised in the management of
epilepsy in France, we cannot conﬁrm that the neurologists in the
ESPERA study were representative of those who manage adult focal
epilepsy patients on polytherapy in France. It is possible that the
ratio of drug-resistant patients imposed by the study protocol
resulted in a higher proportion of epileptologists among the
participating neurologists than in real life and thus a higher
proportion of more severe patients at inclusion. However, theproportion of drug-resistant patients did not differ signiﬁcantly
according to the type of practice or whether the neurologists were
epilepsy specialists or not. The proportion of hospital neurologists
taking part in the study (61%) was similar to that observed
nationally (63%) [34]. Furthermore, 44% of reasons for non-
participation concerned neurologists who had no patients with
epilepsy or few patients on polytherapy. These reasons suggest
that the population studied may be considered as representative
of adult focal epilepsy patients receiving polytherapy in France.
5. Conclusion
The direct cost of focal epilepsy in adults treated with a
combination of AEDs was estimated to be s3850/patient/year in
France. Drug resistance, as deﬁned by the 2009 ILAE criteria,
resulted in a mean extra cost of s2560/patient/year, but this extra
cost varied signiﬁcantly with seizure frequency (from s1060 to
s4320). Despite the many AED combinations available, the choice
of optimal AED combination remains difﬁcult and a large
proportion of focal epilepsies in adults treated with polytherapy
remain uncontrolled. The recent development of consensual
criteria for the deﬁnition of drug resistance, intended to facilitate
epilepsy research, as well as their implementation, should lead to
better guidance in the management of epilepsy patients.
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